Preprint / Version 1

The Impact of Gene Editing and Gene Therapy on the Healthcare of Today

##article.authors##

  • Aarush Gupta Lakeside High School

DOI:

https://doi.org/10.58445/rars.2710

Keywords:

Gene editing, Genetic correction

Abstract

Advancements in gene editing and gene therapy have introduced a new era of possibilities in modern medicine. There are many gene editing methods, with CRISPR receiving most of the spotlight. Genetic correction shows promise for many different diseases and individuals and serves as a bridge between the medicine of today and the medicine of
tomorrow. With rapid progress, the lengthy clinical trial process and the emphasis on ethics ensure the safety of treatments and uphold the value of benefiting patients. The original thoughts on many diseases are evolving as these techniques advance. We are currently witnessing change in the field of medicine through the lens of genetics.

References

Aljabali, A. A. A., El-Tanani, M., & Tambuwala, M. M. (2024). Principles of CRISPR-Cas9

technology: Advancements in genome editing and emerging trends in Drug Delivery. Journal of

Drug Delivery Science and Technology, 92, 105338. https://doi.org/10.1016/j.jddst.2024.105338

Alkanli, S. S., Alkanli, N., Ay, A., & Albeniz, I. (2023). CRISPR/Cas9 Mediated Therapeutic

Approach in Huntington's Disease. Molecular neurobiology, 60(3), 1486–1498.

https://doi.org/10.1007/s12035-022-03150-5

American Society of Gene & Cell Therapy [ASGCT]. (2021, November 2). Gene editing.

https://patienteducation.asgct.org/gene-therapy-101/gene

editing#:~:text=What's%20the%20Difference%3A%20Gene%20Therapy,to%20treat%20or%20

prevent%20disease.

Ayanoğlu, F. B., Elçin, A. E., & Elçin, Y. M. (2020). Bioethical issues in genome editing by

CRISPR-Cas9 technology. Turkish journal of biology = Turk biyoloji dergisi, 44(2), 110–120.

https://doi.org/10.3906/biy-1912-52

Bierlaagh, M. C., Muilwijk, D., Beekman, J. M., & van der Ent, C. K. (2021). A new era for

people with cystic fibrosis. European journal of pediatrics, 180(9), 2731–2739.

https://doi.org/10.1007/s00431-021-04168-y

Carroll, D. (2021). A short, idiosyncratic history of genome editing. Gene and Genome Editing,

, 100002. https://doi.org/10.1016/j.ggedit.2021.100002

Fletcher, L. (2024, July 26). Back to basics - base & prime editing. Front Line Genomics.

https://frontlinegenomics.com/back-to-basics-base-and-prime-editing/

Fu, J., Ji, H. L., Naren, A. P., & Kirk, K. L. (2001). A cluster of negative charges at the amino

terminal tail of CFTR regulates ATP-dependent channel gating. The Journal of Physiology,

(Pt 2), 459–470. https://doi.org/10.1111/j.1469-7793.2001.0459c.xd

Hildebrandt, C. C., & Marron, J. M. (2018). Justice in CRISPR/Cas9 Research and Clinical

Applications. AMA journal of ethics, 20(9), E826–E833.

https://doi.org/10.1001/amajethics.2018.826

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A

programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science

(New York, N.Y.), 337(6096), 816–821. https://doi.org/10.1126/science.1225829

Johns Hopkins Medicine. (n.d.). Genetic disorders.

https://www.hopkinsmedicine.org/health/genetic-disorders

Konstantakos, V., Nentidis, A., Krithara, A., & Paliouras, G. (2022). CRISPR-Cas9 gRNA

efficiency prediction: an overview of predictive tools and the role of deep learning. Nucleic acids

research, 50(7), 3616–3637. https://doi.org/10.1093/nar/gkac192

Lesté-Lasserre, C. (2024, June 13). Lung-targeted CRISPR therapy offers hope for cystic

fibrosis. New Scientist. https://www.newscientist.com/article/2435568-lung-targeted-crispr

therapy-offers-hope-for-cystic-fibrosis/

MedlinePlus. (2022, February 28). What are the ethical issues surrounding gene therapy?

https://medlineplus.gov/genetics/understanding/therapy/ethics/

National Human Genome Research Institute [NHGRI]. (2019, March 13). What are the ethical

concerns of genome editing? https://www.genome.gov/about-genomics/policy-issues/Genome

Editing/ethical-concerns

Razi Soofiyani, S., Baradaran, B., Lotfipour, F., Kazemi, T., & Mohammadnejad, L. (2013).

Gene therapy, early promises, subsequent problems, and recent breakthroughs. Advanced

Pharmaceutical Bulletin, 3(2), 249–255. https://doi.org/10.5681/apb.2013.041

Schleidgen, S., Dederer, H. G., Sgodda, S., Cravcisin, S., Lüneburg, L., Cantz, T., &

Heinemann, T. (2020). Human germline editing in the era of CRISPR-Cas: risk and uncertainty,

inter-generational responsibility, therapeutic legitimacy. BMC medical ethics, 21(1), 87.

https://doi.org/10.1186/s12910-020-00487-1

Sufian, S., & Garland-Thomson, R. (2024, February 20). The Dark Side of CRISPR. Scientific

American. https://www.scientificamerican.com/article/the-dark-side-of-crispr/

Varkey B. (2021). Principles of Clinical Ethics and Their Application to Practice. Medical

principles and practice: international journal of the Kuwait University, Health Science Centre,

(1), 17–28. https://doi.org/10.1159/000509119

Wang, C., Pan, C., Yong, H., Wang, F., Bo, T., Zhao, Y., Ma, B., He, W., & Li, M. (2023).

Emerging non-viral vectors for gene delivery. Journal of Nanobiotechnology, 21(1), 272.

https://doi.org/10.1186/s12951-023-02044-5

Yang, H., Ren, S., Yu, S., Pan, H., Li, T., Ge, S., Zhang, J., & Xia, N. (2020). Methods Favoring

Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand

Breaks. International journal of molecular sciences, 21(18), 6461.

https://doi.org/10.3390/ijms21186461

Downloads

Posted

2025-07-06

Categories